NCT02030860 2025-07-25
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
Clinical Trials
9 trialsNCT03520790 2025-03-21
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02930902 2023-02-09
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03883919 2022-10-05
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
Phase 1 Completed
NCT03300921 2022-03-31
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT01197664 2018-07-02
Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
Wake Forest University Health Sciences
Phase 1 Terminated
NCT00637897 2017-05-30
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT00217477 2014-12-09
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT00258258 2013-02-01
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
Roswell Park Cancer Institute
Phase 1 Terminated